Phase I Study of RO4929097 with Bevacizumab in Patients with Recurrent Malignant Glioma

BACKGROUND: Antiangiogenic therapies for malignant gliomas often result in transient response, and recurrent disease is characterized by adoption of invasive and hypoxic phenotype. The notch signaling pathway is activated in gliomas, and augments cell migration and hypoxic response. Here we report a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Neurooncol
Auteurs principaux: Pan, Edward, Supko, Jeffrey G., Kaley, Thomas J., Butowski, Nicholas A., Cloughesy, Timothy, Jung, Jinkyu, Desideri, Serena, Grossman, Stuart, Ye, Xiaobu, Park, Deric M.
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5571739/
https://ncbi.nlm.nih.gov/pubmed/27826680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-016-2263-1
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires